((II) 含有COUBPY联体的多二烯基复合物作为高效光敏感剂,用于高效光疗的低毒瘤
Diego Abad-Montero1, Albert Gandioso2, Eduardo Izquierdo-García1,2
1Departament de Química Inorgànica i Orgànica, Secció de Química Orgànica, Universitat de Barcelona (UB), and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Martí i Franquès 1-11, E-08028 Barcelona, Spain.
Journal of the American Chemical Society
|February 15, 2025
概括
研究人员开发了基于的新型光敏感剂 (PSs),即使在瘤中常见的低氧 (低氧) 环境中,也有效抗癌. 化合物SCV49在治疗光动力学疗法 (PDT) 治疗固体瘤方面表现有前途.
科学领域:
- 光动力疗法 (PDT) 是一种光动力疗法.
- 癌症研究 癌症研究
- 材料科学 材料科学 材料科学
背景情况:
- 缺氧是瘤攻击性和抗癌疗法的关键因素.
- 光动力疗法 (PDT) 的有效性通常受到瘤缺氧的限制,这是由于依赖氧的活性氧物种 (ROS) 生成.
- 开发氧气独立的PDT剂对于改善癌症治疗结果至关重要.
研究的目的:
- 引入一种新型的 (ruthenium) 的家族,作为强大的光敏感剂 (PSs) 的多基复合物 (COUBPY).
- 评估这些PS的疗效,特别是SCV49,在正常和缺氧癌症模型中.
- 通过光动力学疗法评估SCV49在治疗低氧固体瘤方面的潜力.
主要方法:
- 新型的合成和表征(II) 聚烯基复合物 (COUBPYs).
- 在正常和缺氧条件下对CT-26癌细胞进行体外细胞毒性测定.
- 在CT-26瘤小鼠体内药理动力学,毒理学和抗瘤功效研究.
主要成果:
- 在正常和缺氧条件下,COUBPY复合体在体外对癌细胞表现出高的细胞毒性 (纳米强度).
- 化合物SCV49呈现出很好的光毒性指数 (>30,000),并产生了I型和II型ROS.
- SCV49在低剂量 (3 mg/kg) 和深红光照射下显示出良好的体内药理动力学,良好的耐受性和显著的瘤生长抑制.
结论:
- 新型COUBPY鲁复合物是强大的光敏化剂,在缺氧条件下有效.
- SCV49是低氧固体瘤光动力学治疗的有希望的候选者.
- 进一步的SCV49临床前开发是必要的,用于晚期癌症治疗.
相关概念视频
01:46Electron Transport Chain: Complex I and II
12.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.4K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K